|
nasopharyngeal carcinoma |
78 |
|
survival |
29 |
|
cancer |
25 |
|
chemotherapy |
21 |
|
radiotherapy |
19 |
|
chinese |
18 |
|
lung cancer |
18 |
|
quality of life |
17 |
|
covid-19 |
16 |
|
hepatocellular carcinoma |
16 |
|
intensity-modulated radiation therapy |
16 |
|
whole-exome sequencing |
16 |
|
prognostic marker |
15 |
|
adc |
14 |
|
randomized controlled trial |
14 |
|
tumor microenvironment |
14 |
|
adult |
13 |
|
cancer susceptibility genes |
13 |
|
early-age onset |
13 |
|
humans |
13 |
|
medical sciences |
13 |
|
middle aged |
13 |
|
mst1r |
13 |
|
non-small cell lung cancer |
13 |
|
prognostic factors |
13 |
|
safety |
13 |
|
targeted therapy |
13 |
|
apobec-mediated signature |
12 |
|
cancer survivors |
12 |
|
metastasis |
12 |
|
mind-body intervention |
12 |
|
nf-κb signaling |
12 |
|
plasma ebv dna |
12 |
|
somatic mutation landscape |
12 |
|
survivorship |
12 |
|
treatment outcomes |
12 |
|
capecitabine |
11 |
|
esophageal squamous cell carcinoma (escc) |
11 |
|
nasopharyngeal carcinoma (npc) |
11 |
|
nidogen-2 (nid2) |
11 |
|
promoter hypermethylation |
11 |
|
surgery |
11 |
|
cognitive behavioral therapy |
10 |
|
efficacy |
10 |
|
epstein-barr virus |
10 |
|
family caregiver |
10 |
|
immunotherapy |
10 |
|
incidence |
10 |
|
molecular tumour board |
10 |
|
next-generation sequencing |
10 |
|
precision oncology |
10 |
|
radiology and nuclear medicine |
10 |
|
sequence-directed therapy |
10 |
|
signal transduction |
10 |
|
tissue microarray |
10 |
|
transarterial chemoembolization |
10 |
|
tumor suppressor |
10 |
|
adverse events of special interest (aesi) |
9 |
|
bnt162b2 |
9 |
|
chromatin accessibility |
9 |
|
chromosome 6p |
9 |
|
cisplatin |
9 |
|
cognitive behavioural therapy |
9 |
|
colorectal cancer |
9 |
|
coronavac |
9 |
|
dce-mri |
9 |
|
disease progression |
9 |
|
dw-mri |
9 |
|
ebv |
9 |
|
epidemiology |
9 |
|
family caregivers |
9 |
|
host-virus interaction |
9 |
|
illumina humanmethylation450 |
9 |
|
leucocyte telomere length |
9 |
|
methylome |
9 |
|
mrs |
9 |
|
neoplasm metastasis |
9 |
|
npc risk |
9 |
|
oncology |
9 |
|
recursive partitioning analysis |
9 |
|
stage classification |
9 |
|
survival prediction |
9 |
|
telomere biology |
9 |
|
vaccine |
9 |
|
whole-genome bisulfite sequencing |
9 |
|
aged |
8 |
|
circulating neoplastic cell |
8 |
|
circulating tumor dna |
8 |
|
dosimetric predictors |
8 |
|
female |
8 |
|
head and neck cancer |
8 |
|
immune checkpoint inhibitors |
8 |
|
intensity-modulated radiotherapy |
8 |
|
liquid biopsy |
8 |
|
mortality |
8 |
|
nomogram |
8 |
|
non-metastatic |
8 |
|
outcomes |
8 |
|
pet/ct |
8 |
|
stereotactic body radiation therapy |
8 |
|
tyrosine kinase inhibitors |
8 |
|
unresectable |
8 |
|
-depression |
7 |
|
cancer-related distress |
7 |
|
distress |
7 |
|
drug resistance |
7 |
|
epidermal growth factor receptor |
7 |
|
health-related quality of life |
7 |
|
hong kong |
7 |
|
illness perception |
7 |
|
induction chemotherapy |
7 |
|
insomnia |
7 |
|
long-term cancer survivors |
7 |
|
non-small-cell lung cancer |
7 |
|
occupation |
7 |
|
positron emission tomography |
7 |
|
radiation therapy |
7 |
|
return to work |
7 |
|
sleep disturbance |
7 |
|
sleep quality |
7 |
|
sleep trajectory |
7 |
|
thyroid cancer |
7 |
|
work productivity |
7 |
|
adenocarcinoma |
6 |
|
cetuximab |
6 |
|
concurrent chemoradiotherapy |
6 |
|
decision-making |
6 |
|
economic evaluation |
6 |
|
economic evidence |
6 |
|
follow up |
6 |
|
half-life clearance |
6 |
|
health care |
6 |
|
hypothyroidism |
6 |
|
imrt |
6 |
|
local clinical remission |
6 |
|
magnetic resonance imaging |
6 |
|
metastatic |
6 |
|
multidisciplinary |
6 |
|
palbociclib |
6 |
|
palliative |
6 |
|
patient-derived xenografts |
6 |
|
plasma epstein–barr virus deoxyribonucleic acid |
6 |
|
post-treatment plasma ebv dna |
6 |
|
postradiation malignancies |
6 |
|
prognostic factor |
6 |
|
prognostication |
6 |
|
saha |
6 |
|
simulation models |
6 |
|
5-fluorouracil |
5 |
|
acupuncture |
5 |
|
adenocarcinoma - drug therapy - economics |
5 |
|
adenoviridae - immunology |
5 |
|
aetiology |
5 |
|
antineoplastic combined chemotherapy protocols - administration and dosage - economics - therapeutic use |
5 |
|
autoimmune disease |
5 |
|
cancer immunosuppression |
5 |
|
checkpoint inhibitors |
5 |
|
chemobrain |
5 |
|
chemoradiotherapy |
5 |
|
cheung chau island |
5 |
|
colorectal neoplasms - drug therapy - economics |
5 |
|
cytology and histology |
5 |
|
cytotoxicity |
5 |
|
diffusion magnetic resonance imaging |
5 |
|
diffusion weighted imaging |
5 |
|
diffusion-weighted imaging |
5 |
|
double-negative b cells |
5 |
|
enox2 |
5 |
|
epstein-barr virus infections - immunology - therapy |
5 |
|
epstein-barr virus nuclear antigens - immunology |
5 |
|
folinic acid |
5 |
|
functional assessment |
5 |
|
gastric cancer |
5 |
|
gist |
5 |
|
head and neck cancers |
5 |
|
health care costs - statistics and numerical data |
5 |
|
herpesvirus 4, human - immunology |
5 |
|
hospital authority |
5 |
|
idronoxil |
5 |
|
igra |
5 |
|
illness perceptions |
5 |
|
immunization, passive |
5 |
|
insurance, health, reimbursement - economics |
5 |
|
intravoxel incoherent motion |
5 |
|
late toxicity |
5 |
|
local recurrence |
5 |
|
male |
5 |
|
measurement invariance |
5 |
|
memory t-cells |
5 |
|
metastatic colorectal cancer |
5 |
|
metronomic |
5 |
|
mild cognitive impairment |
5 |
|
multidisciplinary management |
5 |
|
nasopharyngeal neoplasms - immunology - pathology - therapy - virology |
5 |
|
neoplasm staging |
5 |
|
network meta-analysis |
5 |
|
npc |
5 |
|
oncology medical sciences |
5 |
|
optimism |
5 |
|
oral cyclophosphamide |
5 |
|
oxaliplatin |
5 |
|
pooled analysis |
5 |
|
prevalence |
5 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
5 |
|
recurrent |
5 |
|
reirradiation |
5 |
|
reliability |
5 |
|
re‐irradiation |
5 |
|
salvage |
5 |
|
second primary cancer |
5 |
|
societal perspective |
5 |
|
staging |
5 |
|
stretched exponential |
5 |
|
survival outcome |
5 |
|
suv |
5 |
|
symptom distress |
5 |
|
systemic treatment |
5 |
|
t-lymphocytes, cytotoxic - immunology |
5 |
|
therapeutic evaluation |
5 |
|
toxicities |
5 |
|
trends |
5 |
|
trigeminal nerve stimulation |
5 |
|
tuberculosis reactivation |
5 |
|
tumour board |
5 |
|
tumour staging |
5 |
|
unmet need |
5 |
|
validity |
5 |
|
viral matrix proteins - immunology |
5 |
|
adenocarcinoma - genetics |
4 |
|
afatinib |
4 |
|
aged, 80 and over |
4 |
|
asian continental ancestry group - genetics |
4 |
|
association study |
4 |
|
bia |
4 |
|
biomarker |
4 |
|
biopsy, needle |
4 |
|
brachytherapy |
4 |
|
brachytherapy - methods |
4 |
|
cancer management |
4 |
|
carcinoma |
4 |
|
carcinoma, squamous cell - genetics |
4 |
|
chinese medicine |
4 |
|
chromosomes, human, pair 10 - genetics |
4 |
|
chromosomes, human, pair 15 - genetics |
4 |
|
chromosomes, human, pair 17 |
4 |
|
chromosomes, human, pair 5 - genetics |
4 |
|
chromosomes, human, pair 6 - genetics |
4 |
|
cohort studies |
4 |
|
combined modality therapy |
4 |
|
ct |
4 |
|
disease-free survival |
4 |
|
dxa |
4 |
|
dynamic contrast enhanced |
4 |
|
egfr mutations |
4 |
|
erlotinib |
4 |
|
extracapsular spread |
4 |
|
follow-up studies |
4 |
|
fungi |
4 |
|
genetic loci |
4 |
|
genetic predisposition to disease |
4 |
|
genetic risk score |
4 |
|
genetics |
4 |
|
genome-wide association study |
4 |
|
head and neck |
4 |
|
head and neck neoplasms - mortality - pathology - therapy |
4 |
|
herbal medicine |
4 |
|
hyperfractionation |
4 |
|
immunohistochemistry |
4 |
|
infection |
4 |
|
inflammation |
4 |
|
inflammatory mediators |
4 |
|
intensity modulated radiation therapy |
4 |
|
lean mass |
4 |
|
liver metastases |
4 |
|
locally advanced recurrence |
4 |
|
longitudinal |
4 |
|
lung neoplasms - genetics |
4 |
|
lymph node excision - methods |
4 |
|
lymph nodes - pathology |
4 |
|
manual contouring |
4 |
|
meta-analysis |
4 |
|
nasopharyngeal neoplasms - mortality - pathology - therapy |
4 |
|
nasopharyngeal neoplasms - pathology - radiography |
4 |
|
natural history |
4 |
|
neck dissection - methods |
4 |
|
neoplasm invasiveness - pathology |
4 |
|
neoplasm recurrence, local - mortality - pathology - therapy |
4 |
|
nodal tumor control |
4 |
|
polymorphism, single nucleotide |
4 |
|
post-chemoradiation fibrosis |
4 |
|
prospective studies |
4 |
|
psychological distress |
4 |
|
radioembolization |
4 |
|
re-irradiation |
4 |
|
recist |
4 |
|
recurrent nasopharyngeal carcinoma |
4 |
|
risk assessment |
4 |
|
s-1 (combination) |
4 |
|
saliva |
4 |
|
sarcopenia |
4 |
|
smoking |
4 |
|
stage iv |
4 |
|
standard fractionation |
4 |
|
stomach neoplasms |
4 |
|
survival analysis |
4 |
|
suvmax |
4 |
|
systematic review |
4 |
|
telomere length |
4 |
|
tomography, x-ray computed - methods |
4 |
|
traditional chinese medicine |
4 |
|
treatment |
4 |
|
treatment outcome |
4 |
|
tumor doubling time |
4 |
|
tumor growth rate |
4 |
|
tumor staging |
4 |
|
untreated |
4 |
|
volumetric evaluation |
4 |
|
18f-fdg pet |
3 |
|
adoptive cell therapy |
3 |
|
adoptive immunotherapy |
3 |
|
aflibercept |
3 |
|
bevacizumab |
3 |
|
bridging therapy |
3 |
|
cancer treatment |
3 |
|
cancer vaccine |
3 |
|
carotid arteries |
3 |
|
clinical application |
3 |
|
colorectal neoplasms |
3 |
|
complete metabolic response |
3 |
|
consensus |
3 |
|
ct contrast |
3 |
|
cytotoxic t cells |
3 |
|
deglutition disorders |
3 |
|
dose calculation |
3 |
|
dosimetry |
3 |
|
egfr mutation |
3 |
|
end-of-life care |
3 |
|
epidermal growth factor receptor mutation |
3 |
|
epidermal growth factor; stevens-johnson syndrome |
3 |
|
epstein-barr virus dna |
3 |
|
ercc1 |
3 |
|
evidence-based medicine |
3 |
|
graves' ophthalmopathy |
3 |
|
graves’ disease |
3 |
|
hcc diagnosis |
3 |
|
hospice |
3 |
|
immune-related adverse events |
3 |
|
inoperable |
3 |
|
kras wild-type |
3 |
|
levels of evidence |
3 |
|
machine learning |
3 |
|
metastatic colorectal carcinoma |
3 |
|
mirna signature |
3 |
|
nasopharyngeal cancer |
3 |
|
nasopharyngeal neoplasms - ethnology - pathology - radiotherapy |
3 |
|
nasopharyngectomy |
3 |
|
nephrotic syndrome |
3 |
|
non-small-cell lung; receptor |
3 |
|
novel therapy |
3 |
|
oral health |
3 |
|
pain control |
3 |
|
palliative care |
3 |
|
parotid gland - physiopathology - radiation effects |
3 |
|
proteinuria |
3 |
|
radiation dosage |
3 |
|
radiation recall |
3 |
|
radiotherapy, intensity-modulated - adverse effects - methods |
3 |
|
recommendation |
3 |
|
retro-orbital irradiation |
3 |
|
salivation - physiology - radiation effects |
3 |
|
single nucleotide polymorphism |
3 |
|
standard of care |
3 |
|
systemic therapy |
3 |
|
t cells |
3 |
|
thyroid |
3 |
|
thyroid eye disease |
3 |
|
transarterial chemoembolisation |
3 |
|
transarterial radioembolisation |
3 |
|
tyrosine-kinase inhibitor |
3 |
|
unresectable hcc |
3 |
|
3d printed bolus |
2 |
|
adenoid cystic carcinoma |
2 |
|
adjuvant |
2 |
|
adjuvant radiotherapy |
2 |
|
adjuvant therapy |
2 |
|
airway obstruction |
2 |
|
alpha shape |
2 |
|
angiofibroma |
2 |
|
antifungal susceptibility |
2 |
|
antineoplastic agents |
2 |
|
binding free energy |
2 |
|
biofilm |
2 |
|
biopsy |
2 |
|
black fungus |
2 |
|
body motions |
2 |
|
cancer stem cell |
2 |
|
carcinoma, adenoid cystic |
2 |
|
cellular immunity |
2 |
|
challenges |
2 |
|
charged particle therapy |
2 |
|
chest tumors |
2 |
|
computed tomography images |
2 |
|
concurrent |
2 |
|
conformal radiotherapy |
2 |
|
dose-volume histograms |
2 |
|
dosimetric parameter |
2 |
|
dosimetric parameters |
2 |
|
dpyd variant |
2 |
|
egfr mutation database |
2 |
|
endoscopic endonasal approach |
2 |
|
epidermal growth factor receptor (egfr) |
2 |
|
esthesioneuroblastoma |
2 |
|
external beam radiotherapy |
2 |
|
fluoropyrimidines |
2 |
|
gefitinib |
2 |
|
head and neck oncology |
2 |
|
heterogeneity |
2 |
|
intensity-modulated |
2 |
|
inverted papilloma |
2 |
|
ligand–receptor pairs |
2 |
|
liver cancer |
2 |
|
local |
2 |
|
lumpectomy |
2 |
|
lymph node tumor |
2 |
|
lymphoma |
2 |
|
maintenance |
2 |
|
margins |
2 |
|
metastases |
2 |
|
midkine |
2 |
|
modulated electron bolus |
2 |
|
mucosal melanoma |
2 |
|
mutations |
2 |
|
n stage |
2 |
|
nasopharyngeal neoplasms |
2 |
|
neoadjuvant therapy |
2 |
|
neoplasm recurrence |
2 |
|
neuroectodermal carcinoma |
2 |
|
neuroendocrine carcinoma |
2 |
|
non-small-cell lung cancer (nsclc) |
2 |
|
non–small cell lung cancer |
2 |
|
novel |
2 |
|
olfactory neuroblastoma |
2 |
|
oligoprogression |
2 |
|
open approach |
2 |
|
orbit |
2 |
|
overview |
2 |
|
pancreatic neoplasms |
2 |
|
papilloma |
2 |
|
pd-1 |
2 |
|
pedagogy |
2 |
|
pharmacogenetics |
2 |
|
precision medicine |
2 |
|
problem-based learning |
2 |
|
prostate neoplasms |
2 |
|
prostate-specific antigen |
2 |
|
protein surface geometric properties |
2 |
|
radiation |
2 |
|
radiation techniques |
2 |
|
radiation-induced liver injury |
2 |
|
radiosurgery |
2 |
|
resectability |
2 |
|
rhabdomyosarcoma |
2 |
|
risk factors |
2 |
|
sarcoma |
2 |
|
sequential boost |
2 |
|
sinonasal cancer |
2 |
|
sinonasal malignancy |
2 |
|
sinonasal neoplasm |
2 |
|
sinonasal oncology |
2 |
|
sinonasal papilloma |
2 |
|
sinonasal tumor |
2 |
|
sinonasal undifferentiated carcinoma |
2 |
|
skull base |
2 |
|
solid angle |
2 |
|
squamous cell carcinoma |
2 |
|
stereotactic ablative radiotherapy |
2 |
|
subtypes |
2 |
|
subtyping |
2 |
|
surface marker |
2 |
|
surveillance |
2 |
|
temporal lobe necrosis |
2 |
|
trachea |
2 |
|
tumor geometry |
2 |
|
tumor immune microenvironment |
2 |
|
tyrosine kinase inhibitor |
2 |
|
virulence |
2 |
|
volumetric modulated arc therapy |
2 |
|
ablation |
1 |
|
appraisal of guidelines for research and evaluation |
1 |
|
blood-based testing |
1 |
|
carcinoma, non-small-cell lung cancer |
1 |
|
clinical practice guidelines |
1 |
|
cobas assay |
1 |
|
dimer formation |
1 |
|
drug response level |
1 |
|
early access programme |
1 |
|
egfr |
1 |
|
egfr tki-naïve |
1 |
|
egfrt790m mutation |
1 |
|
egft-mutant nsclc |
1 |
|
emission-computed |
1 |
|
eribulin |
1 |
|
euthanasia |
1 |
|
hetero-dimer |
1 |
|
homo-dimer |
1 |
|
interaction fingerprints |
1 |
|
local control |
1 |
|
lq model |
1 |
|
lung neoplasms |
1 |
|
medically assistance in dying |
1 |
|
molecular dynamics simulation |
1 |
|
molecular dynamics simulations |
1 |
|
mucositis - etiology |
1 |
|
multilinear principal component analysis |
1 |
|
mutant allele fraction |
1 |
|
mutation |
1 |
|
nasopharyngeal neoplasms - drug therapy - pathology - radiotherapy |
1 |
|
osimertinib |
1 |
|
pattern of care |
1 |
|
patterns of practice |
1 |
|
pet |
1 |
|
pharyngitis - etiology |
1 |
|
platinum-based doublet chemotherapy |
1 |
|
prognosis |
1 |
|
progression-free survival |
1 |
|
quantitative |
1 |
|
radiation oncology |
1 |
|
radiofrequency ablation |
1 |
|
radiopharmaceuticals/administration & dosage |
1 |
|
radiotherapy dosage |
1 |
|
real world |
1 |
|
regression analysis |
1 |
|
remission induction |
1 |
|
retrospective studies |
1 |
|
sbrt |
1 |
|
single-photon |
1 |
|
stereotactic |
1 |
|
survival rate |
1 |
|
targeted drugs |
1 |
|
technetium tc 99m aggregated albumin |
1 |
|
tomography |
1 |
|
treatment results |
1 |
|
tumor burden |
1 |
|
umbilical veins |
1 |
|
young adult |
1 |
|
yttrium-90 |
1 |
|
yttrium-90 microsphere |
1 |
